Cell loss the same with standard phaco and MICS

Article

Phacoemulsification performed with a standard technique yields no significant differences in endothelial cell loss or endothelial morphology when compared with the procedure performed by bimanual microincision cataract surgery (MICS), according to the results of a study published in the August issue of the Journal of Cataract and Refractive Surgery.

Phacoemulsification performed with a standard technique yields no significant differences in endothelial cell loss or endothelial morphology when compared with the procedure performed by bimanual microincision cataract surgery (MICS), according to the results of a study published in the August issue of the Journal of Cataract and Refractive Surgery.

Rita Mencucci, MD and co-workers from the Department of Oto-Neuro-Ophthalmological Surgical Sciences Eye Clinic, University of Florence, Florence, Italy, randomized 80 patients into two groups; 40 eyes to undergo standard stop and chop phaco and the other 40 eyes to receive stop and chop phaco with bimanual MICS. Corneal endothelial cell counts, coefficient of variation in cell size, hexagonality and pachymetry were assessed preoperatively and then again one and three months postoperatively.

Preoperatively, the mean cell count for the entire sample was 2,245 cells/mm² ± 37 (SE). The mean count decreased by 102 cells at one month and by 144 at three months. The difference between the standard group and the MICS group was 25 cells at baseline, 19 cells at one month and 19 cells at three months. There were no changes in the coefficient of variation or morphology in the overall sample and the pattern of change did not differ between the two groups. Corneal thickness increased by 10.2 µm in the overall sample and approached baseline values by three months with an increase of 3.4 µm. There was no difference in corneal thickness between the two groups.

The authors concluded that no significant differences could be found in corneal endothelial cell loss or endothelial morphology between the two techniques.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.